Sheraton Framingham Hotel &
Conference Center
1657 Worcester Rd,
Framingham,
MA 01701,
United States
Tel: +1 508-879-7200
To book your room at the Sheraton Framingham
Hotel & Conference Center, for the BioTalk US
please follow the link here
Director, Bioprocess Technology and Engineering
AstraZeneca
Irina Ramos is a director of downstream continuous manufacturing, in the Bioprocess Engineering and Technology group at AstraZeneca in Gaithersburg, MD, USA. She has been a key driver of the technology development and implementation strategy for continuous biomanufacturing. Her team works to increase fundamental understanding of various downstream unit operations of drug substance manufacturing. They manage the design, testing and qualification of process equipment and automation of the systems to integrate them.
Dr Ramos holds a BS/MS in Chemical Engineering from University of Porto (Portugal) and a PhD in Chemical & Biochemical Engineering from University of Maryland, Baltimore County (UMBC). For the past 14 years, Dr Ramos’ work in the pharmaceutical industry has spanned from early to late-stage process development and validation, process scalability, CMC and technology transfer to both clinical and commercial manufacturing. With that experience, Irina lead process transfer efforts of the AZ COVID-19 vaccine. She has been involved with NIIMBL Process Intensification program by leading the Control Strategy workstream since 2020 and has been teaching graduate level classes on a Biotechnology Master program since 2015.
Staff Engineer, Biotherapeutics process development
Takeda
I am Rajat Sharma, Ph.D.
I am currently working as the tech-transfer lead for GMP tech-transfers for clinical biologics assets at Takeda, in Lexington, MA.
My academic research involved studying and developing microbial processes for generation of valuable bio-products from fibrous agricultural waste biomass. (MS in Biological and Agricultural Engineering, NCSU, Raleigh, NC,& Ph.D. Food Science and Technology, ISU, Ames, IA).
I started my industrial career at Valent Biosciences in 2017, as a Sr. Fermentation engineer, where I was responsible for end-to-end large-scale upstream bacterial cell cultures.
I joined Takeda in 2020, as a member of the Microbial development team, where I worked on process development and CMC activities for the microbiome and E. coli protein expression programs.
I later moved on to my current role as Tech-Transfer lead for clinical GMP biologics assets, where I am responsible for seamless process transfers from process development/pilot processes to clinical GMP scales for internal and external manufacturing receiving units.
Abstract
Tech-transfer landscape is complex with multiple programs, multiple modalities and a wide network of manufacturing partners (internal/CDMOs). In such an environment, its important to approach a tech-transfer which is inherently a complex activity, with constant pressure of timely completion and being right: “first time”. This presentation is a high-level showcasing of the tools and approaches that can be employed in this complicated TT landscape. The discussion in this presentation will be centered around the following themes: tech-transfer work flow & structure, dos and donts, network strategy, comprehensive process transfer templates, streamlining flow of information, tech-transfer communication strategy, digitalization, and seamless connectivity to electronic management systems in manufacturing.
Head of Cell Culture and Cell Line Development
Biogen
Dr. Sarwat Khattak has 15+ years of experience in the biopharmaceutical industry and has been with Biogen since 2016. She is the Head of Cell Culture Development and Cell Line Development Biologics. Sarwat received her Ph.D. in Chemical Engineering from University of Massachusetts at Amherst and her B.S. in Chemical Engineering from MIT. She has extensive experience in recombinant protein program development through commercialization, cell culture media design, modelling cell culture processes, product quality optimization and continuous manufacturing.
Sr. Staff Process Scientist
Regeneron Pharmaceuticals
• PhD Materials Chemistry from NYU Tandon School of Engineering (2012)
• Joined Regeneron in 2018 - 5 years of BioPharmaceutical Downstream processing and Investigations
• Leads a Team of 10 People involved in Highthroughput Automation and Analytics
• Research experience in the field of Automation of downstream applications, Protein purification, Filtration, Polymer Chemistry, Biodegradable Polymer, Enzyme Immobilization & Bio-catalysis
• Publications include 7 journal articles, 1 book chapter and 1 patent awarded.
Fun Fact
• Prior to Regeneron, Manoj has 5 years of proactive startup skill experience in the biobased chemical industry
• Enjoys cycling.
Operating Partner, Keensight Capital, Principal, RTI Consulting
Keensight Capital
Thomas Ransohoff, M.S., has over 35 years of experience in the biopharmaceutical industry with broad experience in the development and manufacture of biologics and in the management of technology-based start-up firms. He is currently Principal, RTI Consulting, LLC, providing strategic and advisory consulting services to life sciences firms, and an Operating Partner with Keensight Capital. Previously, Mr. Ransohoff was Technical Head, Biologics Franchise for National Resilience, Inc. who he joined through the acquisition of 4th Dimension Bioprocess, where he was a co-founder and COO. Before joining Resilience, Mr. Ransohoff was a Managing Director at BDO and its precursor BioProcess Technology Consultants (BPTC), a leading CMC consulting firm that he helped build over a 20 year period. Prior to that, he held senior level positions at TranXenoGen, Dyax, Repligen, and Xoma. Mr. Ransohoff is a co-founder of several successful start-ups, including 4th Dimension Bioprocess, Tarpon Biosystems and BioFlash Partners, and he holds several board and scientific advisory board appointments. He holds a Bachelor's degree from MIT and a Master's degree from the University of California, Berkeley, both in Chemical Engineering.
Director, MS&T Process Modeling and Analytical Technologies
Bristol-Myers Squibb
Ishaan Shandil is a Biochemical Engineer with 16 years of process and product development, manufacturing and project leadership experience in the Biopharmaceutical industry. Ishaan currently works as an Associate Director Process Engineering MSAT Bristol-Myers Squibb (BMS) where he is responsible for leading projects in Process Engineering and Manufacturing Technology functions. In his role at BMS, he also manages the technical aspects of an external manufacturing relationship and provides CMO oversight. Prior to joining BMS, Ishaan worked for Merck & Co. in roles spanning across R&D and Manufacturing where he designed and developed scalable bioprocesses to manufacture differentiated biologics drug candidates. He also studied and published the impact of process conditions on Glycosylation in monoclonal antibodies and fusion proteins. Ishaan received a MS in Chemical & Biochemical Engineering from University of California Irvine and an MBA from University of Chicago Booth School of Business.
Global Head, Cell Culture Process Development
Sanofi
Henry Lin is a 20+ years veteran in the biopharma industry with deep subject matter expertise in the upstream space as well broad CMC experience spanning pre-clinical to FIH to commercial. He is currently the Global Head of Cell Culture Process Development at Sanofi having responsibilities for all of upstream development in U.S. and France. Prior to Sanofi, Henry was an Executive Director in Biologics Process Development at Merck, Director of Cell Culture Development at Boehringer Ingelheim, and Principal Scientist at Amgen. Henry is a co-inventor on 10 patents and an author of 28 peer-reviewed publications. Henry received his PhD in biochemical engineering from Rice University and bachelor’s degree in bioengineering from UC San Diego.
Sr. Scientist
Amgen
Process Development Scientist at Biogen for 26 years. Coordinate purification development activities for antibodies, fusion proteins, and other types of biological therapeutics. Lead for purification strategy, process development for internal and external programs, process characterization, process validation activities and related global regulatory filings.
Sr. Associate Scientist
Biogen
Spencer is an NCSU graduate with a B.S. in Polymer and Color Chemistry. His first job was working on the Biogen manufacturing floor alternating between upstream and downstream activities, until migrating into a development support role and expressing interest in upstream media development. He currently works with the cell culture development teams at Biogen, providing chemical expertise to investigations and new media formulation construction. As of 2024, Spencer has returned to NCSU to pursue a Masters in Polymer Chemistry exploring the possibility of bringing advances in polymer science into the media design space.
Abstract
Large scale media production presents various challenges to modern bio-pharmaceutical companies. Highly concentrated feed solutions must be constructed with extra care to ensure the solution remains viable throughout a campaign. A 5L small-scale model was designed to capture comparative mixing stress, temperature profiles, and exposure times to reliably replicate precipitation seen during a production run. The data from the scale down model was used to redesign the formulation and process parameters to produce a stable solution at all scales. In addition to automation parameters, floor operations were evaluated for gains in operational efficiency. Implementation of the observed process changes resulted in successful subsequent media preparation and confirmation of the scalable design.
Principal Scientist
Novo Nordisk A/S
- Diploma in Biotechnology at Technical University Braunschweig, Germany
- PhD (Dr. Ing.) in Juergen Hubbuchs group at Research Center in Juelich, Germany
- 2007-2012: Development scientist at Novo Nordisk A/S, Denmark
- > 2012: Principal Scientist in Manufacturing Science and Technology department at Novo Nordisk Denmark
Abstract
Continuous capture chromatography is a chromatographic technique promising higher resin utilization, higher productivity and lower buffer consumption than traditional batch chromatography capture processes. The design of cSMB processes is more challenging than the design of batch processes because each chromatographic phase is influenced by the load from the previous phase and it is in turn influencing the subsequent phase. An iterative approach can be used to identify optimal conditions.
Our current process design approach is based on single column breakthrough curves and feeding the breakthrough data into a model. However, this concept leads to a sub-optimal process as it is based on a single loading flow rate, while effectively, flow rates and amounts in interconnected and parallel load phases can be different so using one flow rate only leads to sub-optimal processes.
We are presenting an approach where different flow rates and different breakthrough curves are used as model inputs together with pressure-flow dependencies for the resin of interest. Using the improved process design, significantly higher productivities were achieved than with the standard procedure. The effect was confirmed for a given in-house model process (mAb purification using Protein A affinity chromatography) where productivities could be increased by approximately 50% which has been confirmed at laboratory scale. The presented approach was also evaluated using mechanistic modelling. Finally, implications of the new cSMB design approach for large-scale manufacturing are discussed.
Senior Principal Scientist
Pfizer
I joined Pfizer in 2013. Currently, I am a Senior Principal Scientist in Pfizer and lead multiple analytical programs from early stage (before clinical study) to commercial approval. My expertise is focusing on analytical strategies such as process characterization and comparability studies. I successfully developed comparability strategies for multiple programs to support clinical or commercial material usage after manufacturing process changes. In addition, I am a key lead/member of analytical comparability expert group in Pfizer to review analytical comparability strategy for biologics. Before joining Pfizer, I received a Ph.D degree in Northeastern University focusing on characterization of post-translational modifications in biologics using LC/MS.
Abstract
During product development and the life cycle of commercial product, process changes are inevitable. Products manufactured using pre- and post- process changes are required to demonstrate comparability per ICH Q5E. A comparability study is a critical tool to ensure the “similarity” of product quality including efficacy, pharmacokinetics, safety and immunogenicity.
In this presentation, a phase appropriate risk assessment of process change will be introduced, followed by comparability strategy based on the risk assessment. Analytical comparability study tools will be discussed including the analytical comparability plan, comparability criteria, execution, data analysis and presentation. Furthermore, non-clinical and clinical comparability will be briefly discussed if there is any analytical difference which may impact product quality. Two comparability case studies will be presented. The first study is to support a new bioprocess to improve product quality and to facilitate larger scale manufacturing. The second one is to support the use of an early process stability study for establishing commercial shelf-life by leveraging the comparability study for an accelerated program. The agency feedback from multiple markets for the case studies will also be discussed.
Associate Director
Takeda Pharmaceuticals
Kyle McHugh received his PhD in Chemical and Biological Engineering from the University of Delaware on cell culture models of neurodegenerative disease. He worked in Upstream Biologics Process Development at Bristol Myers Squibb supporting commercial process development and process characterization for multiple therapeutic protein projects as well as high-throughput optimization, media development, and PAT advancement. Currently, Kyle is an Associate Director of Biotherapeutics Process Development at Takeda Pharmaceuticals in Lexington, MA supporting advancement of platform capabilities and multiple project modalities from FIH through late-stage development.
Abstract
Speed to clinic is critical to enable faster identification of successful early-stage drugs and subsequently faster BLA filing to commercialization. Here we discuss multiple levers to enable faster timelines to IND balancing prioritization of the timeline, business risk, and minimization of pre-investment. From a cell line perspective, strategic choice of source material for exploratory and GLP Tox studies allows for earlier delivery of representative material. Application of automation tools for screening clones and sampling bioreactors allows for more extensive screening and efficient process development. Data connectivity for automated capture and visualization of real-time offline and online process metrics helps to monitor ongoing runs, aggregate data for modelling, and streamline analysis for reports and regulatory submissions. Overall, we demonstrate significant improvements in speed, throughput, and automation for early-stage cell culture process development.
Sr. Director | GDPE (Global Downstream Dev/Pilot Plant/External Mfg)
Bristol Myers Squibb
Angela joined Bristol Myers Squibb in 2013, and over time has taken on increasing responsibilities. Angela and her team of 4 direct reports and 16 full-time employees are responsible for downstream process development for BMS’ growing biologics pipeline. Angela is currently doing a 6-month rotation, where she leads an additional team of 4 direct reports and 28 full-time employees responsible for process analytics. She has been the drug substance matrix lead since 2016 for a monoclonal antibody asset, from mid-stage through commercialization and life cycle management. She has driven several key strategic cross-functional initiatives. Prior to BMS, she worked for several years at Sanofi Genzyme and Regeneron Pharmaceuticals, and has a total of over 19 years of industrial experience. Angela holds M.S. and Ph.D. degrees in Chemical and Biomolecular Engineering from the University of Maryland, and a B.S. in Chemical Engineering from the University of Virginia.
Senior Scientist
AbbVie
Scott H. Altern completed his PhD in Chemical Engineering at Rensselaer Polytechnic Institute (RPI) in Professor Steven Cramer's group (2023). His PhD research was centered on advancing the state-of-the-art in mechanistic modeling of preparative column chromatography and high-throughput process development. Currently, his role is at AbbVie in Worcester, MA where he focuses on mechanistic modeling of preparative chromatography, computational fluid dynamics, and molecular modeling to directly aid in process development. Scott is also highly involved in using high-throughput (HT) experimentation to expedite process development and model generation. Overall, Scott aims to transform industrial bioprocess development using automation and multiscale modeling.
Abstract
In this work, we employed HT instrumentation and multiscale modeling to support early-stage process development for two monoclonal antibodies (mAbs). These molecules had nearly the same isoelectric point but were found to behave differently in CEX. Both antibodies were screened for their dynamic binding capacity (DBC) on POROS XS RoboColumns across a wide range of loading pH and conductivity. Curiously, opposing DBC trends with loading pH and conductivity were observed between the mAbs. Generally, increasing loading pH and conductivity, beyond a certain threshold, results in a reduced DBC in CEX systems. This was consistent with the behavior for mAb B, but contradicted the trends seen for mAb A. Molecular modeling was then employed to identify the molecular features responsible for the unusual screening results. Homology models were constructed for each of the antibodies, from which molecular descriptors were calculated. Descriptors such as net charge and CDR positive charge surface area were correlated with DBC values to confirm that the degree of exclusion was directly related to molecular charge properties. Additionally, mechanistic model parameters were regressed from RoboColumn breakthrough curves to provide additional insight into the unique chromatographic behavior. For instance, trends in surface diffusivity with loading conductivity and pH were examined to determine their contribution to CEX loading performance. Further experimental studies were conducted in order to elucidate the molecular origins of the observed trends. Dynamic light scattering (DLS) experiments were carried out to determine the protein-protein interaction constant over a range of pH and conductivity. Interaction strength was found to be correlated with DBC, suggesting that repulsive forces negatively affect DBC and are dependent on solution conditions. In summary, this study used high-throughput screening and multiscale modeling in conjunction to facilitate CEX PD and improve process understanding from a molecular perspective.
Director, Bioprocess Technology Manufacturing, Science and Technology
Bristol Myers Squibb
Daryl is a director in the Bristol Myers Squibb MS&T drug substance group. He leads a team of process subject matter experts and laboratory scientists supporting the BMS commercial and registrational biologics portfolio. He has a PhD in chemical engineering and 18 years experience in the biotechnology industry.
Abstract
A commercial process was experiencing significant yield and product quality variability. To enhance process SME insights, the enterprise invested in a substantial modelling effort, which included building a data pipeline and conducting both non-proprietary and proprietary process modelling efforts. Initial observations confirmed SME insights and provided quantified targets for future batches. The work for this project highlighted opportunities to improve data quality through addition of PAT tools, expanded data sources, and incorporation of more mechanistic features into models.
Associate Director
Bristol Myers Squibb
Dhanuka Wasalathanthri, Ph.D. is an Associate Director at Bristol Myers Squibb (BMS) where his main role is to serve as the strategy lead for Process Analytical Technology (PAT), High-Throughput Automation and Digital Capabilities at Analytical Development organization. He is a versatile leader with more than 10 years of biotech industry experience in strategic implementation of technologies, CMC analytical development, project management and building high-performing teams in meeting corporate goals. Dhanuka represents BMS at several academic and industry consortia, and he Holds a Ph.D. in Analytical Chemistry from University of Connecticut, USA.
Abstract
Biopharmaceutical landscape is getting increasing complex with a broad spectrum of modalities to meet unmet medical needs, while external geo-political, regulatory, generic competition and sustainability challenges demand acceleration of drug development pipelines. Despite significant advancements in the development and manufacturing workflows for faster and more efficient processes such as intensified and continuous operations, in-process analytical testing is still mainly centric around manual testing. Harnessing the power of automation enables fit-for-purpose and plug-and-play modular units with end-to-end parallel testing of multiple analytical assays with significant improvement in speed and productivity. The concept of robotic process automation (RPA) tools resembles as “Digital Workers” to automatically process, analyze and transcribe analytical results in real time which greatly improves the rapid availability of data to the stakeholders. Complex modalities in the pipeline often require non-platform analytical methods, unique approaches, and upfront investment on method development. Such efforts can be greatly simplified using data interrogation techniques such as Machine Learning and Deep Learning approaches. Herein a vision, roadmap and case studies of automation and digital transformation efforts measured against main KPI’s such as speed and productivity for in-process analytics for biologics are presented.
Principal Data Scientist
Bayer Pharmaceuticals
Shyam Panjwani is currently working as a Principal Data Scientist at Bayer Pharmaceuticals, Berkeley. He holds a PhD degree from University of Houston and a bachelor’s degree from Indian Institute of Technology, Kanpur in chemical engineering. He has 8+ of experience in applying AI/ML/statistics for biologics manufacturing processes, biological assays and process development. Before joining Bayer, he worked with Halliburton and Air Products.
Abstract
The biopharmaceutical industry is increasingly turning to data science to optimize manufacturing processes and enhance product quality. This presentation explores two innovative case studies that leverage data science to improve efficiency in biologics manufacturing.
The first case study focuses on a cloud-based predictive modeling application designed to enhance the predictability of mammalian cell culture processes. By forecasting bioreactor potency from at-line process parameters over a multiple-day horizon, this application quantifies prediction uncertainty and provides valuable insights for process control, ultimately enhancing productivity and product quality.
The second case study presents a novel framework for assessing the out-of-specification (OOS) risk associated with drug product potency. This framework utilizes a cloud-based statistical software application to streamline the evaluation of alternate potency targets, reducing manual errors and improving the efficiency of risk assessments.
Together, these case studies illustrate the transformative impact of data science on the biopharmaceutical manufacturing landscape.
Director Biologics Process Development, BPR&D
Merck
Experienced R&D Director with a demonstrated history of evaluating and delivering Process Analytics and Automation solutions to clinical and commercial biologics manufacturing.
Carrie has been with Lonza for 17 years. Her focus at Lonza includes commercial biomanufacturing SME support and technology transfer of clinical to commercial manufacturing. She has been a key contributor to the Lonza R&D efforts in intensified, continuous mAb manufacturing. Her current role is leading a multidisciplinary team in the investigation and development of novel bioprocessing modalities with a focus on process analytical technologies. Recently she was in charge of the design and build of a stand alone state of the art facility for the research of novel technology and automation. The Process Innovation Center was completed in March 2024. As the Head of the PIC, Carrie is responsible for directing PAT and Automation research, Industry and Academic collaborations in the New England Biotech Ecosystem.
She has over 25 years in industry primarily focused on development of chromatography and separations technology with associated analytical method development. She is a member of numerous industry consortia and collaborative efforts with the intent to drive forward innovations to advance the current biomanufacturing processes.
Associate Director Bioprocess R&D
Lonza
Experienced R&D Director with a demonstrated history of evaluating and delivering Process Analytics and Automation solutions to clinical and commercial biologics manufacturing.
Carrie has been with Lonza for 17 years. Her focus at Lonza includes commercial biomanufacturing SME support and technology transfer of clinical to commercial manufacturing. She has been a key contributor to the Lonza R&D efforts in intensified, continuous mAb manufacturing. Her current role is leading a multidisciplinary team in the investigation and development of novel bioprocessing modalities with a focus on process analytical technologies. Recently she was in charge of the design and build of a stand alone state of the art facility for the research of novel technology and automation. The Process Innovation Center was completed in March 2024. As the Head of the PIC, Carrie is responsible for directing PAT and Automation research, Industry and Academic collaborations in the New England Biotech Ecosystem.
She has over 25 years in industry primarily focused on development of chromatography and separations technology with associated analytical method development. She is a member of numerous industry consortia and collaborative efforts with the intent to drive forward innovations to advance the current biomanufacturing processes.
Associate Vice President, Head of Biologics Process Research & Development
Merck
Experienced pharma leader with extensive knowledge in biologics CMC, small molecule CMC, commercial manufacturing, bioanalytics, GLP lab management and GMP manufacturing facility operation.
Senior Cell Culture Engineer II
Biogen
Brandon Moore is an Upstream Process Engineer with 13 years of experience working on the development, characterization, and optimization of mammalian cell culture biomanufacturing processes with a specific focus on advanced process control and process analytics. Throughout this work, a recurring theme that has surfaced is the need for new approaches towards improving process understanding using advanced modelling and troubleshooting techniques which take the unique complexities and performance of cell-based systems into account.
Abstract
Variability was observed in the cell culture performance of inoculum stages in batches of a large-scale HEK293 commercial therapeutic protein production process. The impact was significant enough in result in termination of several batches, as insufficient cell mass was present to inoculate subsequent stages. Root cause analysis and bench-scale laboratory studies indicated that the large-scale media preparations were the root cause of the growth impact, and that the magnitude of impact varied between media bottles within a batch. Additionally, variability was observed between multiple batches of media which used identical filtration and preparation operations.
The investigation summarized in this case study examined each step of the media preparation and filtration processes. Bottle-to-bottle variability in media performance was replicated under laboratory conditions when using a specific 0.1µm polyethersulfone (PES) pre-filter which was part of the filtration platform for Chinese hamster ovary (CHO) processes. Interestingly, the first few bottles of media filtered were found to support normal growth—performance impact was first observed in later bottles, becoming more severe before eventually resolving. This behavior is inconsistent with the widely-held assumption that the magnitude of process impact would be greatest in the first volume of media passing through a filter. Replacing the filter was found to result in restoration of consistently high cell growth in the previously-impacted inoculum stages. This case study highlights the importance of the robust evaluation of filtration schemes between media formulations for different cell lines and the strategic application of platform process elements.
Lead Statistician CMC Development
UCB
Alexandre currently works within the Centre of Expertise CMC Statistics at UCB Pharma. He is responsible the development and implementation of statistical and modelling approaches for biologics and medical devices projects throughout their lifecycle, from the early stages of technical development all the way to commercial manufacturing.
Process Engineer, Clinical Manufacturing
Pfizer
Alessandra Molinaro is a Process Engineer with six years of experience in the biopharmaceutical industry specializing in cell culture operations at the clinical scale. Alessandra has a Bachelor of Science in purification at the clinical-scale and GMP Manufacturing. Yianni has a Bachelor of Science in Chemical Engineering from University of Massachusetts Lowell and a Master of Science in Biotechnology from Worcester Polytechnic Institute.
Abstract
Implementation of a new technology in a GMP manufacturing environment present several distinct challenges, including adhering to regulatory requirements, implementing new methods into the existing systems, as well as management of new risks. In this work, we present a case study of the implementation of the One-Pot Capture Redox (OPCR), a novel technology for the production of multispecifics, into a clinical production facility.
This presentation will discuss the challenges of introducing the OPCR technology at the clinical manufacturing scale. Based on the success of implementation of the new technology, a harmonized approach has been identified to enable other new technologies to be implemented simpler in GMP manufacturing.
Process Engineer, Clinical Manufacturing
Pfizer
Alessandra Molinaro is a Process Engineer with six years of experience in the biopharmaceutical industry specializing in cell culture operations at the clinical scale. Alessandra has a Bachelor of Science in Chemical Engineering from the University of Massachusetts Lowell and a Master of Science in Biotechnology from Worcester Polytechnic Institute.
Abstract
Implementation of a new technology in a GMP manufacturing environment present several distinct challenges, including adhering to regulatory requirements, implementing new methods into the existing systems, as well as management of new risks. In this work, we present a case study of the implementation of the One-Pot Capture Redox (OPCR), a novel technology for the production of multispecifics, into a clinical production facility.
This presentation will discuss the challenges of introducing the OPCR technology at the clinical manufacturing scale. Based on the success of implementation of the new technology, a harmonized approach has been identified to enable other new technologies to be implemented simpler in GMP manufacturing.
Principal Scientist, Bioprocess Development
Abbvie
Jian Ren is a Principal Scientist in the Manufacturing Science and Technology (MSAT) organization at AbbVie Bioresearch Center in Worcester, MA. She leads process tech transfer, validation, and manufacturing support activities for the downstream manufacturing process for late phase and commercial biologics programs, including monoclonal antibodies, bispecific antibodies and fusion proteins. Prior to MSAT, she led purification process development, tech transfer, and validation activities for early-to-late-phase biologics projects. Prior to AbbVie, her research focused on the development and optimization of polymeric membranes and modules for various separation applications. Jian holds a PhD in Chemical Engineering from the University of Connecticut.
Senior Principal Research Scientist
Abbvie
Dr. Lihua Yang has been at AbbVie for over 20 years and is currently a Senior Principal Research Scientist and Group Leader within the Purification Development Department in Product Development Science and Technology organization. Dr. Yang led 25+ early and late phase programs and numerous innovation initiatives on biologics in areas of mAb, bispecific, antibody-drug conjugates and gene therapy. She has extensive experience in bioprocess development, characterization, validation, tech transfer to global GMP manufacture, process internalization, product launch, IND and BLA filing. Besides leading strong functional and cross-functional teams to deliver innovative and improved purification process, Dr. Yang is also a subject matter expert in bioanalytical assay development and protein characterization. Dr. Yang holds a Ph.D degree in Chemistry and Chemical Biology from Northeastern University, and a BS degree in Physical Chemistry from Peking University in China.
OPERATING PARTNER
Keensight Capital
With over 35 years of professional experience in the biopharma industry, his experience includes serving as the Technical Head of the biologicals franchise within Resilience, overseeing all activities related to recombinant protein and monoclonal antibody projects and technology development initiatives.
Prior to that, Tom has held various C-suite positions at other biopharma companies such as 4th Dimension Bioprocess, Inc. (co-founder and COO), BioFlash Partners (President and CEO), TranXenGen, Inc. (Vice President, Operations), Dyax Corp (Vice President, Program Management and Product Development).
Tom is a regular speaker at leading biopharma conferences, has published over 20 academic articles and has also developed and filed several patents, related to innovative biopharma manufacturing processes.
Tom holds a B.S in Chemical Engineering from MIT and a M.S. in Chemical Engineering from the University of California, Berkeley.
Director, MS&T Process Modeling and Analytical Technologies
Bristol Myers Squibb
Ishaan Shandil is a Biochemical Engineer with 16 years of process and product development, manufacturing and project leadership experience in the Biopharmaceutical industry. Ishaan currently works as an Associate Director Process Engineering MSAT Bristol-Myers Squibb (BMS) where he is responsible for leading projects in Process Engineering and Manufacturing Technology functions. In his role at BMS, he also manages the technical aspects of an external manufacturing relationship and provides CMO oversight. Prior to joining BMS, Ishaan worked for Merck & Co. in roles spanning across R&D and Manufacturing where he designed and developed scalable bioprocesses to manufacture differentiated biologics drug candidates. He also studied and published the impact of process conditions on Glycosylation in monoclonal antibodies and fusion proteins. Ishaan received a MS in Chemical & Biochemical Engineering from University of California Irvine and an MBA from University of Chicago Booth School of Business.
Senior Scientist Pivotal Biologics Drug Substance Technologies
Amgen
Ravi Vattepu is a Senior Scientist in the Pivotal Biologics Process Development group, focused on purification process development of biologics. He holds a PhD in Chemistry from Wichita State University and completed postdoctoral research at Harvard Medical School, where his work focused on antibody glycosylation and the role of IgG subclasses in inflammation.